Pilot corpus: NIH-funded biomedical datasets. Any DOI can be scored on demand — network effects sharpen as coverage grows.

Growth factors maintain intratumoral heterogeneity and drive therapeutic resistance in triple-negative breast cancer

Cell Reports(2025)10.1016/j.celrep.2025.116826Source: DataRank Database

Growth factors maintain intratumoral heterogeneity and drive therapeutic resistance in triple-negative breast cancer is a research paper published in Cell Reports (2025). On theSindex it has a DataRank of 0. It has been cited 1 time.

N/A

0DataRank · unranked

Scored on demand from live citation data

Open Access1 citations

Download PDF

Cite:

Linked data & code

gen cellosaurus doi

DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?

›Methodology & internals

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Pipeline:MetadataData-paper checkEnrichmentCitation networkScoring

Enrichment:Funding (9 grants)Impact (FWCI 0.48)OA: goldTopics (39)IDs (PubMed, PMC, OpenAlex)Annotations (3)SDGs (1)

FAIR Checklist

Context only (not used in score)

Findable (1/2)

Has DOI

Accessible (1/2)

Open Access

Interoperable (0/2)

Reusable (0/3)

FAIR checklist signals are shown for context only and do not affect DataRank scoring.

Run a calibrated FAIR evaluation for this paper →

We only score data papers we can read in full — never from an abstract alone.

Authors (12)

Rebecca Smith ORCID,Elmar Bucher ORCID,Mark Dane ORCID,Chloe L. Bowman ORCID,Eric J. Carlson ORCID

Live enrichment

PubMed:41477765 PMC:PMC12959317 OpenAlex:https://openalex.org/W7117784541

National Institutes of Health National Cancer Institute

Grant: HG008100

National Institutes of Health Common Fund

Grant: U54CA209988

American Cancer Society Inc

Grant: RSG-22-060-01-MM

NHGRI NIH HHS

Grant: U54 HG008100

Knight Cancer Institute, Oregon Health and Science University

Prospect Creek Foundation

Cancer Early Detection Advanced Research Center, Knight Cancer Institute, Oregon Health and Science University

Lady Margaret Hall, University of Oxford

National Institutes of Health

FWCI

0.48

Citation Percentile

0.7%

Citation Trend

2026

goldLicense: cc-by

journalhttps://doi.org/10.1016/j.celrep.2025.116826

publisherhttps://doi.org/10.1016/j.celrep.2025.116826

publisherhttps://api.elsevier.com/content/article/PII:S2211124725015980?httpAccept=text/xml

publisherhttps://api.elsevier.com/content/article/PII:S2211124725015980?httpAccept=text/plain

repositoryhttps://pubmed.ncbi.nlm.nih.gov/41477765

Fields of Study

HER2/EGFR in Cancer ResearchLiver physiology and pathologyTGF-β signaling in diseasesTriple Negative Breast NeoplasmsHumansDrug Resistance, NeoplasmFemaleHepatocyte Growth FactorCell Line, TumorTumor MicroenvironmentAnimalsPyrimidinonesPyridonesMice

MeSH Terms

AnimalsFemaleHumansPyridonesPyrimidinonesHepatocyte Growth FactorDrug Resistance, NeoplasmCell Line, TumorMiceTumor MicroenvironmentTriple Negative Breast Neoplasms

Keywords

Hepatocyte growth factorBreast cancerTumor microenvironmentTrametinibBasal (medicine)MAPK/ERK pathwayMesenchymal stem cellDrug resistanceTherapeutic approachMicroenvironmentTriple Negative Breast CancerTumor HeterogeneityTherapeutic ResistanceCp: Cancer

Sustainable Development Goals

SDG 0: Good health and well-being

Growth factors maintain intratumoral heterogeneity and drive therapeutic resistance in triple-negative breast cancer

FAIR Checklist

Authors (12)

Funding (9 grants)

Impact

Open Access

Topics

Annotations (Europe PMC)